Dronedarone: Basic Pharmacology and Clinical Use.

Card Electrophysiol Clin 2016 06 19;8(2):453-65. Epub 2016 Mar 19.

Department of Medicine, Université de Montréal and Montreal Heart Institute, 5000 Rue Belanger, Montreal, Québec H1T 1C8, Canada; Heart Rhythm Services, Department of Medicine, University of British Columbia, 2775 Laurel Street, Vancouver, British Columbia V5Z 1M9, Canada. Electronic address:

Dronedarone is the newest antiarrhythmic drug approved for the maintenance of sinus rhythm in patients with nonpermanent atrial fibrillation (AF). It is a multi-channel blocker with diverse electrophysiologic properties. Dronedarone decreases the incidence of AF recurrence and the ventricular rate during recurrence. Dronedarone decreases rates of cardiovascular hospitalizations in patients with paroxysmal and persistent AF. Dronedarone increases mortality in patients with permanent AF and those with moderate-severe heart failure, and should thus be avoided in these populations. Dronedarone is less effective than amiodarone but also has less toxicity. Direct comparison with other antiarrhythmic drugs is not available.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccep.2016.02.008DOI Listing
June 2016
7 Reads

Publication Analysis

Top Keywords

dronedarone decreases
8
dronedarone
6
cardiovascular hospitalizations
4
rates cardiovascular
4
hospitalizations patients
4
patients paroxysmal
4
persistent dronedarone
4
paroxysmal persistent
4
decreases rates
4
rate recurrence
4
properties dronedarone
4
electrophysiologic properties
4
decreases incidence
4
incidence recurrence
4
dronedarone increases
4
ventricular rate
4
recurrence dronedarone
4
increases mortality
4
amiodarone toxicity
4
effective amiodarone
4

Similar Publications